A A Adjei
Affiliation: Mayo Clinic
Anwar S, Tan W, Hong C, Admane S, Dozier A, Siedlecki F, et al
. Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events. Cancers (Basel). 2017;9: pubmed publisher
..04). Conclusions: Lower (worse) EORTC QLQ-C30 score at baseline is associated with SAE occurrence during phase 1 oncology trials. ..
Jazieh K, Molina J, Allred J, Yin J, Reid J, Goetz M, et al
. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Invest New Drugs. 2018;: pubmed publisher
..Tipifarnib is currently being evaluated in HRAS mutant tumors, providing a potential opportunity to further test this combination. ..
Adjei A. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003;3:145-56 pubmed
..More importantly, vitamin supplementation has not demonstrated any adverse efficacy. This review discusses the biochemistry and clinical activity of pemetrexed. ..
Adjei A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004;10:4276s-4280s pubmed
..Low level dietary supplement of folic acid and vitamin B12 has significantly decreased the mucosal and bone marrow toxicity of pemetrexed without compromising its antitumor effect. ..
Adjei A, Davis J, Erlichman C, Svingen P, Kaufmann S. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000;6:2318-25 pubmed
..Our results indicate that unprocessed HDJ-2 and prelamin A should be suitable markers of FT inhibition in clinical samples. ..
Adjei A. Current data with pemetrexed (Alimta) in non-small-cell lung cancer. Clin Lung Cancer. 2003;4 Suppl 2:S64-7 pubmed
..Approval for pemetrexed in combination with cisplatin in advanced mesothelioma is expected within the next 12 months. This review discusses the activity of pemetrexed in NSCLC...
Soria J, Adjei A, Bahleda R, Besse B, Ferte C, Planchard D, et al
. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced . Eur J Cancer. 2017;86:186-196 pubmed publisher
..9%) patients. Combining pictilisib with various standard-of-care first-line treatment regimens is feasible from a safety perspective in patients with NSCLC, and encouraging preliminary anti-tumour activity was observed. ..
Adjei A, Reid J, Erlichman C, Sloan J, Pitot H, Alberts S, et al
. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs. 2002;20:297-304 pubmed
..Subsequent studies revealed that PZA inhibits removal of platinum-DNA adducts in cultured A549 cells. Based on these results, we undertook a phase I study of the combination of PZA and carboplatin (CBDCA)...
Adjei A, Croghan G, Erlichman C, Marks R, Reid J, Sloan J, et al
. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003;9:2520-6 pubmed
..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...